"Economic evaluation of the combination of talimogene laherparepvec (T-vec) plus ipilimumab (T-vec+Ipi) versus ipilimumab (Ipi) in patients (pts) with advanced unresectable melanoma."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Economic evaluation of the combination of talimogene laherparepvec (T-vec) plus ipilimumab (T-vec+Ipi) versus ipilimumab (Ipi) in patients (pts) with advanced unresectable melanoma.

e21545Background: A recent trial comparing T-vec+Ipi vs Ipi found no differential benefit in progression-free survival (PFS) (HR 0.83, 95%CI 0.56–1.23), but noted objective response rates (ORR) of ... Click to show full abstract

Keywords: evaluation combination; ipi; vec ipi; combination talimogene; economic evaluation; vec

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended